FR2902010B1 - Utilisation de la 1,7 dimethylxanthine pour la fabrication d'un medicament psychoanaleptique non anxiogene destine au traitement d'un trouble neuropsychiatrique - Google Patents

Utilisation de la 1,7 dimethylxanthine pour la fabrication d'un medicament psychoanaleptique non anxiogene destine au traitement d'un trouble neuropsychiatrique

Info

Publication number
FR2902010B1
FR2902010B1 FR0605189A FR0605189A FR2902010B1 FR 2902010 B1 FR2902010 B1 FR 2902010B1 FR 0605189 A FR0605189 A FR 0605189A FR 0605189 A FR0605189 A FR 0605189A FR 2902010 B1 FR2902010 B1 FR 2902010B1
Authority
FR
France
Prior art keywords
psychoanaleptic
anxiogenic
dimethylxanthine
medicament
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0605189A
Other languages
English (en)
Other versions
FR2902010A1 (fr
Inventor
Jean Costentin
Lucilla Mansuy
Pierre Sokoloff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Université de Rouen Normandie
Original Assignee
Pierre Fabre Medicament SA
Université de Rouen Normandie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA, Université de Rouen Normandie filed Critical Pierre Fabre Medicament SA
Priority to FR0605189A priority Critical patent/FR2902010B1/fr
Priority to TW096120502A priority patent/TW200815013A/zh
Priority to PCT/EP2007/055668 priority patent/WO2007144315A1/fr
Priority to CA002654891A priority patent/CA2654891A1/fr
Priority to US12/304,377 priority patent/US20090325984A1/en
Priority to JP2009514766A priority patent/JP2009539921A/ja
Priority to EP07730023A priority patent/EP2026812A1/fr
Priority to ARP070102566A priority patent/AR061446A1/es
Publication of FR2902010A1 publication Critical patent/FR2902010A1/fr
Application granted granted Critical
Publication of FR2902010B1 publication Critical patent/FR2902010B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR0605189A 2006-06-12 2006-06-12 Utilisation de la 1,7 dimethylxanthine pour la fabrication d'un medicament psychoanaleptique non anxiogene destine au traitement d'un trouble neuropsychiatrique Expired - Fee Related FR2902010B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR0605189A FR2902010B1 (fr) 2006-06-12 2006-06-12 Utilisation de la 1,7 dimethylxanthine pour la fabrication d'un medicament psychoanaleptique non anxiogene destine au traitement d'un trouble neuropsychiatrique
TW096120502A TW200815013A (en) 2006-06-12 2007-06-07 Use of 1,7-dimethylxanthine for the manufacture of a non-anxiogenic psychoanaleptic drug for the treatment of a neuropsychiatric disorder
CA002654891A CA2654891A1 (fr) 2006-06-12 2007-06-08 Utilisation de 1,7-dimethylxanthine pour la fabrication d'un medicament psychoanaleptique non anxiogene pour le traitement d'un trouble neuropsychiatrique
US12/304,377 US20090325984A1 (en) 2006-06-12 2007-06-08 Use of 1,7-dimethylxanthine for the manufacture of a non-anxiogenic psychoanaleptic drug for the treatment of a neuropsychiatric disorder
PCT/EP2007/055668 WO2007144315A1 (fr) 2006-06-12 2007-06-08 Utilisation de 1,7-diméthylxanthine pour la fabrication d'un médicament psychoanaleptique non anxiogène pour le traitement d'un trouble neuropsychiatrique
JP2009514766A JP2009539921A (ja) 2006-06-12 2007-06-08 神経精神障害の治療用の非不安誘発性精神賦活薬の製造のための１，７−ジメチルキサンチンの使用
EP07730023A EP2026812A1 (fr) 2006-06-12 2007-06-08 Utilisation de 1,7-diméthylxanthine pour la fabrication d'un médicament psychoanaleptique non anxiogène pour le traitement d'un trouble neuropsychiatrique
ARP070102566A AR061446A1 (es) 2006-06-12 2007-06-12 Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0605189A FR2902010B1 (fr) 2006-06-12 2006-06-12 Utilisation de la 1,7 dimethylxanthine pour la fabrication d'un medicament psychoanaleptique non anxiogene destine au traitement d'un trouble neuropsychiatrique

Publications (2)

Publication Number Publication Date
FR2902010A1 FR2902010A1 (fr) 2007-12-14
FR2902010B1 true FR2902010B1 (fr) 2008-08-22

Family

ID=37592447

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0605189A Expired - Fee Related FR2902010B1 (fr) 2006-06-12 2006-06-12 Utilisation de la 1,7 dimethylxanthine pour la fabrication d'un medicament psychoanaleptique non anxiogene destine au traitement d'un trouble neuropsychiatrique

Country Status (8)

Country Link
US (1) US20090325984A1 (fr)
EP (1) EP2026812A1 (fr)
JP (1) JP2009539921A (fr)
AR (1) AR061446A1 (fr)
CA (1) CA2654891A1 (fr)
FR (1) FR2902010B1 (fr)
TW (1) TW200815013A (fr)
WO (1) WO2007144315A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014065446A1 (fr) * 2012-10-24 2014-05-01 (주)라이프앤진 Composition amincissante de décomposition de la graisse par la caféine et la paraxanthine
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12622889B2 (en) 2016-04-19 2026-05-12 Axcess Global Sciences, Llc S-β-hydroxybutyrate esters for improving metabolic function
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
US12599579B2 (en) 2016-04-19 2026-04-14 Axcess Global Sciences, Llc Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) * 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
AU2021210442A1 (en) * 2020-01-23 2022-09-15 Px Ing, Llc Paraxanthine-based bioactive composition and method of use thereof
TW202227085A (zh) * 2020-09-14 2022-07-16 美商萊罕製藥股份有限公司 氘代副黃嘌呤(paraxanthine)及其用途
US12194046B2 (en) 2021-03-09 2025-01-14 Lennham Pharmaceuticals, Inc. D9-caffeine compositions and uses thereof
JP2024511169A (ja) * 2021-03-26 2024-03-12 ピーエックス・アイエヌジー，エルエルシー 運動誘発性精神疲労を低減するためのパラキサンチンの使用
EP4313056A4 (fr) * 2021-03-31 2025-02-19 Px Ing, Llc Utilisation de paraxanthine pour améliorer les performances chez les joueurs de jeux vidéos
CA3217058A1 (fr) 2021-04-29 2022-11-03 Jeffrey Dietrich Compositions et leurs procedes de production
CA3226805A1 (fr) * 2021-07-27 2023-02-02 Ralf Jager Compositions de substitution de cafeine a base de paraxanthine et methode associee d'utilisation chez des sujets a metabolisme cafeique lent
US20230113817A1 (en) * 2021-10-12 2023-04-13 Ingenious Ingredients, LP Dileucine compositions and methods of use thereof for fat loss
WO2023064511A1 (fr) 2021-10-13 2023-04-20 Ingenious Ingredients, LP Composition bioactive à base de paraxanthine et son procédé d'utilisation
US20230165868A1 (en) * 2021-11-28 2023-06-01 Ingenious Ingredients, LP Paraxanthine-based compositions for enhancing muscle function, nitric oxide signaling, and/or muscle glycogen levels
WO2024187191A2 (fr) * 2023-03-09 2024-09-12 Ingenious Ingredients, LP Compositions de dileucine et leurs procédés d'utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001252606B2 (en) * 2000-04-26 2005-07-07 Eisai R&D Management Co., Ltd. Medicinal compositions promoting bowel movement
EP1611238B1 (fr) * 2003-02-26 2009-06-17 The John Hopkins University Composes modulant le transport du glutamate et procedes associes
US7960544B2 (en) * 2005-12-16 2011-06-14 Ironwood Pharmaceuticals, Inc. Useful indole compounds
JP2009528059A (ja) * 2006-02-28 2009-08-06 メタボロン インコーポレイテッド 筋萎縮性側索硬化症に関するバイオマーカー及びそれらを使用する方法

Also Published As

Publication number Publication date
EP2026812A1 (fr) 2009-02-25
TW200815013A (en) 2008-04-01
AR061446A1 (es) 2008-08-27
US20090325984A1 (en) 2009-12-31
JP2009539921A (ja) 2009-11-19
WO2007144315A1 (fr) 2007-12-21
CA2654891A1 (fr) 2007-12-21
FR2902010A1 (fr) 2007-12-14

Similar Documents

Publication Publication Date Title
LT2878297T (lt) Medikamentai, skirti fibrozinių ligų gydymui arba prevencijai
BRPI0810646A2 (pt) " compostos farmacêuticos ".
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
FR2910351B1 (fr) Catalyseur d'hydrotraitement, son procede de preparation et son utilisation.
FR2887139B1 (fr) Dispositif de traitement d'un vaisseau sanguin.
FR2925541B1 (fr) Element prefabrique pour unite d'habitation.
BRPI0808246A2 (pt) "fralda descartável".
FR2908827B1 (fr) Cone d'entree pour turbomachine
FR2926208B1 (fr) Ancillaire, notamment pour la pose d'une prothese de hanche.
FR2936442B1 (fr) Dispositif pour la fabrication d'une piece en materiau composite de forme complexe.
FR2896422B1 (fr) Systeme de drainage pour le traitement de l'hydrocephalie
EP1889618A4 (fr) Médicament combiné pour le traitement du diabète
NO20053147D0 (no) Forsterkningsring.
FR2898272B1 (fr) Utilisation de derives du 3,5-seco-4-nor-cholestrane pour l'obtention d'un medicament cytoprotecteur
FR2881437B1 (fr) Procede pour le diagnostic/pronostic d'un syndrome septique
FR2915100B1 (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson
EP1952811A4 (fr) Utilisation de l'eriocalyxine b pour la fabrication de medicaments destines au traitement de la leucemie
DK1750744T3 (da) Lægemiddel til behandling af svampeinfektioner, især aspergillose
FR2923064B1 (fr) Dispositif pour stimuler la memoire d'un patient.
FR2926023B1 (fr) Utilisation d'une homoproteine de la famille bicoid pour le traitement du glaucome.
FR2904756B1 (fr) Dispositif de maintien des seins pour application medicale.
FR2883180B1 (fr) Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
CL2007001456A1 (es) Uso de compuestos derivados de 3,5-difenil 1,2,4-triazoles para el tratamiento de hemocromatosis hereditaria.
FR2884716B1 (fr) Utilisation de l'azithromycine pour la fabrication d'un medicament destine au traitement des infections oculaires
FR2893321B1 (fr) Mecanisme de pousse pour machine i.s

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20140228